Get the Stockscreener App
0.00
100.00%
-0.0002
T 2 Biosystems Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
See More
Previous Close:
$0.0002
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$N/A
Revenue:
$7.68M
Net Income/Loss:
$-42.95M
P/E Ratio:
0.00
EPS:
-6.4055
Net Cash Flow:
$-36.62M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.0007
52-Week Range:
$0.00
$0.0222
T 2 Biosystems Inc Stock (TTOO) Company Profile
Name
T 2 Biosystems Inc
Sector
Industry
Phone
-
Address
-
Compare TTOO vs TMO, DHR, IDXX, A, NTRA
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TTOO
T 2 Biosystems Inc
|
0.00 | 0 | 7.68M | -42.95M | -36.62M | -6.4055 |
TMO
Thermo Fisher Scientific Inc
|
568.26 | 211.18B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
191.50 | 134.62B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
544.32 | 42.94B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
138.57 | 39.14B | 7.23B | 1.41B | 1.09B | 4.979 |
NTRA
Natera Inc
|
261.99 | 37.52B | 2.50B | -226.32M | 71.51M | -1.6412 |
T 2 Biosystems Inc Stock (TTOO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-21 | Downgrade | Alliance Global Partners | Buy → Neutral |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Nov-26-19 | Downgrade | Janney | Buy → Neutral |
| Aug-01-19 | Downgrade | Alliance Global Partners | Buy → Neutral |
| Jul-31-19 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-31-19 | Downgrade | Janney | Buy → Neutral |
| May-16-19 | Initiated | Alliance Global Partners | Buy |
| Mar-08-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-01-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| May-30-18 | Reiterated | H.C. Wainwright | Buy |
| May-29-18 | Reiterated | WBB Securities | Strong Buy |
| Mar-29-18 | Reiterated | H.C. Wainwright | Buy |
| Jan-29-18 | Initiated | Goldman | Neutral |
| Oct-18-17 | Initiated | H.C. Wainwright | Buy |
| Mar-15-17 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-10-16 | Resumed | Leerink Partners | Mkt Perform |
| Nov-02-16 | Reiterated | Cantor Fitzgerald | Buy |
| Jul-20-16 | Upgrade | WBB Securities | Buy → Strong Buy |
| Jun-22-16 | Upgrade | WBB Securities | Speculative Buy → Buy |
| Apr-12-16 | Reiterated | Canaccord Genuity | Buy |
| Feb-17-16 | Initiated | WBB Securities | Speculative Buy |
View All
T 2 Biosystems Inc Stock (TTOO) Latest News
Rapid Micro Biosystems to Announce Second Quarter 2026 Financial Results on August 7, 2026 - Yahoo! Finance Canada
TTOO Price History for T2 Biosystems CS Stock - Barchart.com
Lyme Disease Testing Market Analysis Highlights Growth To $16.46 Billion By 2030 At 9% CAGR - openPR.com
Imagion Biosystems, Siemens Healthineers Extend Imaging Agent Collaboration - Imaging Technology News
Price to sales forward of T2 Biosystems, Inc. – OTC:TTOO - TradingView
Price to earnings forward of T2 Biosystems, Inc. – OTC:TTOO - TradingView
Enterprise value to revenue forward of T2 Biosystems, Inc. – OTC:TTOO - TradingView
Price to book forward of T2 Biosystems, Inc. – OTC:TTOO - TradingView
T2 Biosystems, Inc. Actuals & Estimates (OTC:TTOO) - TradingView
T2 Biosystems, Inc. Actuals & Estimates (LSE:0A57) - TradingView
Imagion Biosystems Secures AU$3.75M in Capital Raise Following FDA Clearance of Phase 2 Clinical Trial - Business Wire
Lyme Disease Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Abbott, Bio-Rad Labs, Covance Inc.F. Hoffmann-La Roche AG, T2 Biosystems - Barchart.com
BioSystems Engineering (01355) plans to conduct a rights issue on a "2-for-1" basis, aiming to raise up to approximately HK$39 million in net proceeds. - Moomoo
Spot Biosystems Launches with $40 Million Financing and World-First Non-Viral Delivery of Full-Length Dystrophin in Animal Models and Human Patients with DMD - BioSpace
Rapid Carbapenem-Resistant Organism Identification Market Growth to Accelerate by 2035 Driven by Multiplex Syndromic PanelsNews and Statistics - IndexBox
Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review - Medianet News Hub
Rapid Micro Biosystems Announces Pricing of Up to Approximately $32 Million Underwritten Offering - Yahoo Finance
T2 Biosystems Inc (OTCM:TTOO) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
T2 Biosystems Inc (OTCM:TTOO) Stock Earnings Transcripts - GuruFocus
T2 Biosystems Inc (OTCM:TTOO) Stock Price & 30 Year Financial Data - GuruFocus
Rapid Micro Biosystems, Inc. (RPID) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Number of shareholders of T2 Biosystems, Inc. – OTC:TTOO - TradingView
Leica Biosystems unveils next-generation digital pathology scanner and AI-powered QC software - Drug Discovery News
Financial Analysis: Biostage (OTCMKTS:BSTG) and T2 Biosystems (NASDAQ:TTOO) - defenseworld.net
T2 Biosystems (NASDAQ:TTOO) Stock Passes Below 200-Day Moving Average – Time to Sell? - Defense World
Aspect Biosystems secures $79-million in federal funding to advance 3-D tissue printing technology - The Globe and Mail
TTOO (T2 Biosystems) PB Ratio : (As of Mar. 27, 2026) - GuruFocus
TTOO stock $0.0001 on NASDAQ 19 Mar 2026 Market Closed: top losers risk - Meyka
T2 Biosystems2026 Funding Rounds & List of Investors - Tracxn
T2 Biosystems, Inc. Announces Intent to Complete Winding Down of Operations - marketscreener.com
TTOO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
New hires at Rapid Micro Biosystems get 205K RSUs, 168K options - Stock Titan
Critical Review: Acutus Medical (NASDAQ:AFIB) & T2 Biosystems (NASDAQ:TTOO) - Defense World
Medical-imaging company Imagion Biosystems Lodges IND with FDA for Phase 2 Trial of MagSense® HER2 targeted imaging agent - BioSpace
T2 Biosystems announces intent to wind down operations - marketscreener.com
Targeted Imaging Agent Submitted to FDA for IND Application - Imaging Technology News
TTOO Stock Price and Chart — OTC:TTOO - TradingView
T2 Biosystems announces plans to license technology to expand its leadership - Intellectia AI
T2 Biosystems (NASDAQ:TTOO) Shares Cross Below Two Hundred Day Moving Average – Should You Sell? - Defense World
Lyme Disease Diagnostic Devices Market Valuation Expected - openPR.com
Aspect Biosystems expands partnership with Novo Nordisk to develop diabetes treatment - The Globe and Mail
Rapid Micro Biosystems, Inc. (NASDAQ:RPID) Stocks Shoot Up 25% But Its P/S Still Looks Reasonable - simplywall.st
T2 Biosystems (NASDAQ:TTOO) versus Minerva Surgical (NASDAQ:UTRS) Head-To-Head Review - Defense World
T2 Biosystems (TTOO) Earnings Calendar_Earnings Analysis_Financial Report and Earnings Call - Tiger Brokers
More than 4,600 Massachusetts biotech workers lost jobs in 2025 as industry contracts - The Business Journals
Rapid Micro Biosystems, Inc.'s (NASDAQ:RPID) last week's 10% decline must have disappointed private equity firms who have a significant stake - simplywall.st
Ocean Dx sepsis test matches gold standard in early study - BioWorld News
DHAI Stock Price and Chart — OTC:DHAI - TradingView
Rapid Micro Biosystems And 2 Promising Penny Stocks To Watch - Yahoo Finance
NAVBQ Stock Price and Chart — OTC:NAVBQ - TradingView
Imagion Biosystems (ASX:IBX) gets ready for Phase 2 - Stocks Down Under
T 2 Biosystems Inc Stock (TTOO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.02%
0.35%
Cap:
|
Volume (24h):